David E. Avigan
Distinguished in Smoldering Multiple Myeloma

Dr. David E. Avigan

Internal Medicine | Oncology
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
On Staff At
33 Years of Experience
Distinguished in Smoldering Multiple Myeloma
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Avigan is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Avigan has been practicing medicine for over 33 years and is rated as a Distinguished provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Yale University School Of Medicine
Residency
Columbia Presbyterian Medical Center
Specialties
Internal Medicine
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Memorial Sloan- Kettering Cancer Center
Hospital Affiliations
Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center
Languages Spoken
English
Hebrew
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 7, Boston, MA 02215
Call: 617-667-9920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: GO-203-2C, Decitabine
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Enrollment Status: Completed
Publish Date: April 03, 2023
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 27, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients
Enrollment Status: Unknown
Publish Date: September 08, 2022
Intervention Type: Biological
Study Drug: TEG002
Study Phase: Phase 1
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: Busulfan, Fludarabine, Tacrolimus, Methotrexate, GM-CSF-Positive GVAX Vaccine
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation
Enrollment Status: Completed
Publish Date: January 23, 2019
Intervention Type: Biological, Radiation, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

121 Total Publications

Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
Journal: Blood cancer discovery
Published: June 05, 2025
View All 121 Publications
Similar Doctors
Paul G. Richardson
Elite in Smoldering Multiple Myeloma
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology
Elite in Smoldering Multiple Myeloma
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

20 Prospect St, Suite 2, 
Milford, MA 
 (26.0 miles away)
508-473-1190
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Richardson is a Hematologist Oncology specialist and an Oncologist in Milford, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is currently accepting new patients.

Elite in Smoldering Multiple Myeloma
Dr. Omar Nadeem
Hematology | Oncology
Elite in Smoldering Multiple Myeloma
Dr. Omar Nadeem
Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Omar Nadeem is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Nadeem has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Nadeem is currently accepting new patients.

Elite in Smoldering Multiple Myeloma
Dr. Andrew J. Yee
Hematology Oncology | Hematology | Oncology
Elite in Smoldering Multiple Myeloma
Dr. Andrew J. Yee
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Yee is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Yee is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Vertebroplasty, and Bone Marrow Aspiration. Dr. Yee is currently accepting new patients.

VIEW MORE SMOLDERING MULTIPLE MYELOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Avigan's expertise for a condition
ConditionClose
  • Elite
  • Acute Myeloid Leukemia (AML)
    Dr. Avigan is
    Elite
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Multiple Myeloma
    Dr. Avigan is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Distinguished
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Avigan is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • B-Cell Lymphoma
    Dr. Avigan is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Classical Hodgkin Lymphoma
    Dr. Avigan is
    Distinguished
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Graft Versus Host Disease (GvHD)
    Dr. Avigan is
    Distinguished
    . Learn about Graft Versus Host Disease (GvHD).
    See more Graft Versus Host Disease (GvHD) experts
  • Hodgkin Lymphoma
    Dr. Avigan is
    Distinguished
    . Learn about Hodgkin Lymphoma.
    See more Hodgkin Lymphoma experts
  • Leukemia
    Dr. Avigan is
    Distinguished
    . Learn about Leukemia.
    See more Leukemia experts
View All 9 Distinguished Conditions
  • Advanced
  • Acute Erythroid Leukemia (AEL)
    Dr. Avigan is
    Advanced
    . Learn about Acute Erythroid Leukemia (AEL).
    See more Acute Erythroid Leukemia (AEL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Avigan is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Bone Marrow Aspiration
    Dr. Avigan is
    Advanced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Bone Marrow Transplant
    Dr. Avigan is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Childhood Acute Myeloid Leukemia
    Dr. Avigan is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Avigan is
    Advanced
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
View All 24 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Avigan is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Mountain Sickness
    Dr. Avigan is
    Experienced
    . Learn about Acute Mountain Sickness.
    See more Acute Mountain Sickness experts
  • Acute Promyelocytic Leukemia
    Dr. Avigan is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Adult T-Cell Leukemia
    Dr. Avigan is
    Experienced
    . Learn about Adult T-Cell Leukemia.
    See more Adult T-Cell Leukemia experts
  • Agranulocytosis
    Dr. Avigan is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Angioimmunoblastic T-cell Lymphoma
    Dr. Avigan is
    Experienced
    . Learn about Angioimmunoblastic T-cell Lymphoma.
    See more Angioimmunoblastic T-cell Lymphoma experts
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.